New Thiazolidine-4-One Derivatives as SARS-CoV-2 Main Protease Inhibitors

Antonella Messore,Paolo Malune,Elisa Patacchini,Valentina Noemi Madia,Davide Ialongo,Merve Arpacioglu,Aurora Albano,Giuseppe Ruggieri,Francesco Saccoliti,Luigi Scipione,Enzo Tramontano,Serena Canton,Angela Corona,Sante Scognamiglio,Annalaura Paulis,Mustapha Suleiman,Helmi Mohammed Al-Maqtari,Fatma Mohamed A. Abid,Sarkar M. A. Kawsar,Murugesan Sankaranarayanan,Roberto Di Santo,Francesca Esposito,Roberta Costi

DOI: https://doi.org/10.3390/ph17050650

IF: 4.6

2024-05-18

Pharmaceuticals

Abstract:It has been more than four years since the first report of SARS-CoV-2, and humankind has experienced a pandemic with an unprecedented impact. Moreover, the new variants have made the situation even worse. Among viral enzymes, the SARS-CoV-2 main protease (Mpro) has been deemed a promising drug target vs. COVID-19. Indeed, Mpro is a pivotal enzyme for viral replication, and it is highly conserved within coronaviruses. It showed a high extent of conservation of the protease residues essential to the enzymatic activity, emphasizing its potential as a drug target to develop wide-spectrum antiviral agents effective not only vs. SARS-CoV-2 variants but also against other coronaviruses. Even though the FDA-approved drug nirmatrelvir, a Mpro inhibitor, has boosted the antiviral therapy for the treatment of COVID-19, the drug shows several drawbacks that hinder its clinical application. Herein, we report the synthesis of new thiazolidine-4-one derivatives endowed with inhibitory potencies in the micromolar range against SARS-CoV-2 Mpro. In silico studies shed light on the key structural requirements responsible for binding to highly conserved enzymatic residues, showing that the thiazolidinone core acts as a mimetic of the Gln amino acid of the natural substrate and the central role of the nitro-substituted aromatic portion in establishing π-π stacking interactions with the catalytic His-41 residue.

pharmacology & pharmacy,chemistry, medicinal

What problem does this paper attempt to address?

The paper attempts to address the issue of developing new SARS-CoV-2 main protease (Mpro) inhibitors to overcome the limitations of existing drugs and improve the treatment efficacy against COVID-19 and its variants. Specifically: 1. **Continuous mutation of the coronavirus**: Despite the availability of vaccines, the coronavirus continues to mutate, leading to ongoing transmission, necessitating the development of new antiviral drugs. 2. **Mpro as a drug target**: The main protease Mpro of SARS-CoV-2 plays a crucial role in viral replication and is highly conserved among coronaviruses, making it an ideal target for developing broad-spectrum antiviral drugs. 3. **Limitations of existing drugs**: Currently approved drugs like nirmatrelvir have some drawbacks, such as the need to be used within 5 days of symptom onset, potential drug interactions, and the possible emergence of resistant variants. To address these issues, researchers synthesized a series of new thiazolidin-4-one derivatives and evaluated their inhibitory activity against SARS-CoV-2 Mpro through in vitro experiments. Additionally, molecular docking studies were conducted to reveal the key structural features of these compounds binding to Mpro.

New Thiazolidine-4-One Derivatives as SARS-CoV-2 Main Protease Inhibitors

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and its Variants Displaying Potent Antiviral Activity

Synthesis and biological evaluation of novel Peptidomimetic inhibitors of the coronavirus 3C-like protease

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors

Discovery of Peptidomimetic Spiropyrrolidine Derivatives As Novel 3clpro Inhibitors Against SARS-CoV-2

Design of novel and highly selective SARS-CoV-2 main protease inhibitors

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2

Discovery of 3-Oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin Derivatives As SARS-CoV-2 Main Protease Inhibitors Through Virtual Screening and Biological Evaluation.

Ligand-based design, synthesis, computational insights, and in vitro studies of novel N-(5-Nitrothiazol-2-yl)-carboxamido derivatives as potent inhibitors of SARS-CoV-2 main protease

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development

In Silico Identification of Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro)

Thiazole/Thiadiazole/Benzothiazole Based Thiazolidin-4-One Derivatives as Potential Inhibitors of Main Protease of SARS-CoV-2

Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents

Design, Synthesis, X-ray Crystallography, and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease

Structural and mechanistic insights into Main protease (Mpro) dimer interface destabilization inhibitor: Unveiling new therapeutic avenues against SARS-CoV-2

Novel 1,3-Indanedione-Thiazole Hybrids as Small-Molecule SARS-COV-2 Main Protease Inhibitors With Potential anti-Coronaviral Activity

Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease

Synthesis, molecular docking analysis, molecular dynamic simulation, ADMET, DFT, and drug likeness studies: Novel Indeno[1,2-b]pyrrol-4(1H)-one as SARS-CoV-2 main protease inhibitors

Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions